PET/MR imaging to study liver diseases

PET/MR imaging to study liver diseases

Webinar overview

This webinar will present different approaches to study liver diseases with simultaneous PET/MR Imaging. Our first speaker Professor Erik Shapiro from Michigan State University will focus on liver function and how new ways of combining PET and MR imaging using hepatospecific metal chelate PET tracers and contrast enhanced MRI potentially can be used to observe early changes in liver function during disease.

The second part of the webinar is presented by Viktoria Ehret and Usevalad Ustsinau from Medical University of Vienna. Their talk will focus on liver metabolism and how combining metabolic targeted PET tracers and deuterium metabolic imaging (DMI) can be used to enhance our understanding of organ-level metabolic processes in vivo.

The talks will be presented live followed by a Q&A session.

Register here

Speakers

Erik M. Shapiro, PhD

Associate Chair and Professor of Radiology, Michigan State University

Erik Shapiro is Associate Chair of Research and a Professor in the Department of Radiology at Michigan State University. His Molecular and Cellular Imaging Laboratory (MCIL) develops and uses magnetic resonance imaging (MRI), positron emission tomography (PET), and x-ray computed tomography (CT) for molecular and cellular imaging of biological phenomena, regenerative medicine, and early detection of disease.

Dr. Shapiro graduated from the State University of New York at Binghamton with a B.S. in chemistry and holds a M.S. and Ph.D. in chemistry from the University of Pennsylvania. He conducted his post-doctoral work in molecular imaging at the National Institutes of Health. He was Assistant Professor of Diagnostic Radiology at Yale University School of Medicine prior to joining MSU. He is a recipient of an NIH Director’s New Innovator Award and the Distinguished Investigator Award from The Academy for Radiology & Biomedical Imaging Research.

Viktoria Ehret

MSc, Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Viktoria Ehret is pursuing her Ph.D. degree, working in the Preclinical Imaging Laboratory at the Medical University of Vienna, Austria. Ms. Ehret earned her Master's degree in Physics with a specialization in Medical Physics from Eberhard Karls University in Tübingen, Germany.

Usevalad Ustsinau

MSc, Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria

Usevalad Ustsinau is pursuing his Ph.D. degree, working in the Preclinical Imaging Laboratory at the Medical University of Vienna, Austria. Mr. Ustsinau completed his Master degree in Biomedical Engineering at Brno University of Technology in the Czech Republic.

Who should attend

Researchers, postgraduate students, and principal investigators working in academia as well as researchers working with drug and tracer development in the pharmaceutical sector. Some basic understanding of PET and MRI imaging is required.

FIRST TALK

PET/MRI of liver function using hepatospecific metal chelates

  • What is the function of the liver and how is it affected by disease
  • How can we measure specific aspects of liver function
  • What are the benefits and disadvantages of using MRI to measure liver function
  • Turning MRI contrast agents into PET agents
  • How can simultaneous PET/MRI be used to better measure liver function

SECOND TALK

Multiparametric Imaging for Assessment of Hepatic Glucose and Lipid Metabolism using PET/MR and DMI Techniques

In this talk, we will present a comprehensive evaluation of glucose and free fatty acid metabolism at the organ level, utilizing state-of-the-art imaging technology. With our in-house preclinical Bruker BioSpec 94/30 USR MRT scanner, equipped with a PET-Insert, we can observe physiological processes, perform functional metabolic imaging, and accurately measure receptor, transporter, and enzyme densities using specific metabolic PET-tracers. In combination with the recently introduced MR-based in vivo deuterium metabolic imaging (DMI), we can provide localized assessments of hepatic glucose and lipid metabolism, taking the anatomical structure of the body into account. This approach represents a significant advancement in metabolic imaging and has the potential to greatly enhance our understanding of organ-level metabolic processes.

Other Webinars from Bruker BioSpin - NMR, EPR and Imaging

Life Science Webinars by Subject Matter